Viatris anticipates the acquisitions adding $1 billion in sales by 2028, according to a Nov. 7 news release from the company. Oyster Point Pharma and Famy Life Sciences have an aggregate purchase price of $700 million to $750 million.
Viatris is aiming to close the Oyster Point acquisition in the first quarter of 2023, pending regulatory approval.
“Building on our success in the U.S. market, we are excited to join Viatris to now bring the strengths of Oyster Point to help build a leading global ophthalmology business,” Jeff Nau, PhD, CEO of Oyster Point, said in the release. “We believe that together we will meaningfully shape the future of eye care to address the unmet needs of patients with ophthalmic disease and the eye care professionals who take care of them.”
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
